drugset / Trial / NCT01373086

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086

Phase 2 Terminated 19 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of LFF269 compared to placebo after treatment in subjects with essential hypertension.

Timeline

Start
2011-05
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Eplerenone Unknown 50 mg
Subject LFF269 Unknown

Indications